AzTrials
AzTrials

Condition

Advanced Solid Tumors Clinical Trials

Studies of advanced solid tumors, matched by condition name and medical subject headings. Start with those open to enrolment.

6,306 registered studies

In numbers

Open to volunteers
1,611
Active
2,085
With results posted
856
All registered
6,306

Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.

Open to volunteers

All 1,611
  • Advanced Solid Tumor

    A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

    • Recruiting
    • Age: 18 years and older
    • Phase 1

    This study will evaluate the safety and efficacy of DS-1103a combination therapy in participants with advanced solid tumors.

    Trial name
    NCT05765851
    Testing
    DS-1103a, T-DXd
    Where
    15 sites in United States, Canada and 4 more
    Volunteers
    128 people
    Sponsor
    Daiichi Sankyo
    Can I take part? NCT05765851
  • Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma

    Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

    • Recruiting
    • Age: 18 to 120 years
    • Phase 1/2

    Background: Head and neck cancers (HNCs) account for about 5% of all cancers worldwide. They grow in the mouth, throat, nasal cavity, or salivary glands. Prostate cancer is the most common cancer in men in the United States.

    Conditions
    Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Paranasal Sinus Neoplasms, Nasopharyngeal Carcinoma
    Trial name
    NCT07667400
    Testing
    SX-682, DTX
    Where
    United States
    Volunteers
    120 people
    Sponsor
    National Cancer Institute (NCI)
    Can I take part? NCT07667400
  • Advanced Solid Tumors

    Personalized KXV01 Lentinvivo (TCR) Injection as the Therapy for Advanced Solid Tumors

    • Recruiting
    • Age: 18 to 70 years
    • Phase 1
    • Injection or infusion

    This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KXV01 TCR Lentinvivo for patients with advanced solid tumors.

    Trial name
    NCT07275853
    Testing
    KXV01 TCR Lentinvivo Injection
    Where
    China
    Volunteers
    30 people
    Sponsor
    TCRx Therapeutics Co.Ltd
    Can I take part? NCT07275853
  • Breast Neoplasms, Colorectal Neoplasms

    A Study of LY4257496 in Participants With Cancer (OMNIRAY)

    • Recruiting
    • Age: 18 years and older
    • Phase 1

    The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor…

    Conditions
    Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
    Trial name
    OMNIRAY (NCT07114601)
    Testing
    LY4257496, Standard of Care Anticancer Therapies, LY4257529
    Where
    33 sites in United States, Canada and 5 more
    Volunteers
    421 people
    Sponsor
    Eli Lilly and Company
    Can I take part? OMNIRAY
  • Cancer, PDAC - Pancreatic Ductal Adenocarcinoma

    A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

    • Recruiting
    • Age: 18 years and older
    • Phase 1

    The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.

    Conditions
    Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer)
    Trial name
    NCT06835569
    Testing
    ALTA3263, cetuximab, mFOLFOX6
    Where
    14 sites in United States
    Volunteers
    448 people
    Sponsor
    Alterome Therapeutics, Inc.
    Can I take part? NCT06835569
  • Advanced Solid Cancer

    Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors

    • Recruiting
    • Age: 18 to 70 years
    • Phase 1
    • Injection or infusion

    This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KXV01 TCR Lentinvivo for patients with advanced solid tumors.

    Trial name
    NCT07196579
    Testing
    KXV01 TCR Lentinvivo Injection
    Where
    China
    Volunteers
    30 people
    Sponsor
    TCRx Therapeutics Co.Ltd
    Can I take part? NCT07196579
  • Advanced Lung Cancer, Lung Metastasis

    mRNA Vaccine for Advanced Lung Cancer and Pulmonary Metastases of Solid Tumors

    • Recruiting
    • Age: Up to 99 years
    • Early Phase 1

    BMD006 is an off-the-shelf antitumor mRNA vaccine targeting lung cancer and lung metastatic solid tumors. This is a single-center, open-label, dose-escalation clinical trial.

    Trial name
    NCT06928922
    Testing
    BMD006 monotherapy, BMD006 in combination with Immuno-Oncology (IO) therapy (Dose Escalation), BMD006 in combination with Immuno-Oncology (IO) therapy (Dose Expansion)
    Where
    China
    Volunteers
    83 people
    Sponsor
    Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    Can I take part? NCT06928922
  • Solid Tumor, Advanced Solid Tumor

    An Investigational Study of BON-106 in Adults With Advanced or Metastatic Solid Tumors

    • Not yet recruiting
    • Age: 18 years and older
    • Phase 1

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BON-106 in adults with advanced or metastatic solid tumors.

    Conditions
    Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor
    Trial name
    NCT07893535
    Testing
    BON-106
    Volunteers
    96 people
    Sponsor
    BeOne Medicines
    Can I take part? NCT07893535
  • Advanced Solid Tumors

    JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration

    • Recruiting
    • Age: 18 years and older
    • Phase 1/2

    This study is to evaluate the safety and tolerability of pan-KRAS inhibitor JAB-23E73 Monotherapy and in Combination with Other Agents in adult participants with advanced solid tumors

    Trial name
    NCT06973564
    Testing
    JAB-23E73, Cetuximab
    Where
    4 sites in United States
    Volunteers
    344 people
    Sponsor
    Jacobio Pharmaceuticals Co., Ltd.
    Can I take part? NCT06973564
  • Locally Advanced or Metastatic Solid Tumors

    A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors

    • Recruiting
    • Age: 18 years and older
    • Phase 1/2

    This is an early development study of ASP388B in people with solid tumors. In this study, ASP388B will be given to people for the first time. It will be given by itself or together with standard cancer therapies.

    Trial name
    NCT07730021
    Testing
    ASP388B, Pembrolizumab, Carboplatin
    Where
    4 sites in United States, Japan
    Volunteers
    392 people
    Sponsor
    Astellas Pharma Global Development, Inc.
    Can I take part? NCT07730021

Completed, with results posted

All 538

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in